Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731–40.

Article  CAS  PubMed  Google Scholar 

Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24:482–91.

Article  PubMed  Google Scholar 

Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:211–2.

Article  Google Scholar 

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347–61.

Article  PubMed  PubMed Central  Google Scholar 

Pascual-Morena C, Cavero-Redondo I, Reina-Gutiérrez S, Saz-Lara A, López-Gil JF, Martínez-Vizcaíno V. Prevalence of neuropsychiatric disorders in Duchenne and Becker muscular dystrophies: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2022;103:2444–53.

Article  PubMed  Google Scholar 

Pascual-Morena C, Cavero-Redondo I, Álvarez-Bueno C, Jiménez-López E, Saz-Lara A, Martínez-García I, et al. Global prevalence of intellectual developmental disorder in dystrophinopathies: a systematic review and meta-analysis. Dev Med Child Neurol. 2022;65:734–44.

Article  PubMed  Google Scholar 

Kipke J, Birnkrant DJ, Jin JB, Aneja A, Bahler RC. A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy. Pediatr Pulmonol. 2021;56:782–95.

Article  PubMed  Google Scholar 

Pascual-Morena C, Cavero-Redondo I, Álvarez-Bueno C, Mesas AE, Pozuelo-Carrascosa D, Martínez-Vizcaíno V. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review. Ann Clin Transl Neurol. 2020;7:1738–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391:451–61.

Article  CAS  PubMed  Google Scholar 

Biggar WD, Skalsky A, McDonald CM. Comparing deflazacort and prednisone in Duchenne muscular dystrophy. J Neuromuscul Dis. 2022;9:463–76.

Article  PubMed  PubMed Central  Google Scholar 

Liu G, Lipari P, Mollin A, Jung S, Teplova I, Li W, et al. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models. Hum Mol Genet. 2024;33:211–23.

Article  PubMed  Google Scholar 

Grounds MD, Lloyd EM. Considering the promise of vamorolone for treating Duchenne muscular dystrophy. J Neuromuscul Dis. 2023;10:1013–30.

Article  PubMed  PubMed Central  Google Scholar 

Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013;5:1569–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keam SJ. Vamorolone: first approval. Drugs. 2024;84:111–7.

Article  CAS  PubMed  Google Scholar 

Elhalag RH, Motawea KR, Talat NE, Rouzan SS, Shah J. Efficacy of vamorolone in treatment of Duchene muscle dystrophy: a meta-analysis. Front Neurol. 2023;14:1107474.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. John Wiley and Sons; 2008. Available from: https://research.monash.edu/en/publications/cochrane-handbook-for-systematic-reviews-of-interventions-cochran. [Accessed 28 Oct 2020].

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097.

Article  PubMed  PubMed Central  Google Scholar 

Eldridge S, Campbell MK, Campbell MJ, Drahota-Towns A, Giraudeau B, Higgins JPT, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. 2016. Available from: https://researchportal.port.ac.uk/en/publications/revised-cochrane-risk-of-bias-tool-for-randomized-trials-rob-20-a. [Accessed 20 Sep 2024].

NHLBI, NIH. Study quality assessment tools. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. [Accessed 17 Apr 2021].

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018;136:140–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019;93:e1312–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17: e1003222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol. 2022;79:1005–14.

Article  PubMed  PubMed Central  Google Scholar 

Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open. 2022;5: e2144178.

Article  PubMed  PubMed Central  Google Scholar 

Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial. Neurology. 2024;102: e208112.

Article  PubMed  PubMed Central  Google Scholar 

Mcdonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48:357–68.

Article  PubMed  PubMed Central  Google Scholar 

Ayyar Gupta V, Pitchforth JM, Domingos J, Ridout D, Iodice M, Rye C, et al. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS One. 2023;18: e0283669.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazzone E, Martinelli D, Berardinelli A, Messina S, D’Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20:712–6.

Article  PubMed  Google Scholar 

Mcdonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013;48:343–56.

Article  PubMed  PubMed Central  Google Scholar 

Hamuro L, Chan P, Tirucherai G, AbuTarif M. Developing a natural history progression model for Duchenne muscular dystrophy using the six-minute walk test. CPT Pharmacometrics Syst Pharmacol. 2017;6:596–603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zambon AA, Gupta VA, Ridout D, Manzur AY, Baranello G, Trucco F, et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev Med Child Neurol. 2022;64:979–88.